Korean J Urol.  2010 Nov;51(11):752-756.

Predictive Factors of Prostate Cancer at Repeat Biopsy in Patients with an Initial Diagnosis of Atypical Small Acinar Proliferation of the Prostate

• Ryu JH
• Kim YB
• Lee JK
• Kim YJ
• Jung TY

Abstract

PURPOSE
The factors that predict prostate cancer detection on repeat biopsy were evaluated in patients with atypical small acinar proliferation (ASAP) on the initial biopsy.
MATERIALS AND METHODS
From 2003 to 2008, 3,130 men with suspected prostate cancer underwent a prostate needle biopsy, and 244 (7.8%) were diagnosed as having ASAP. One hundred seventy of 244 patients were rebiopsied at least once more. They were classified into a prostate cancer group and a noncancer group according to the final pathological diagnosis. The database of rebiopsied patients included age, initial prostate-specific antigen (PSA), PSA density (PSAD), PSA velocity (PSAV), total prostate volume (TPV), and transitional zone volume of the prostate (TZV). We compared differences in the aforementioned parameters between the 2 groups.
RESULTS
A total of 57 patients (33.5%) with ASAP were ultimately shown to have prostate cancer. Univariate analysis showed that PSAD (p=0.002), PSAV (p=0.001), TPV (p=0.035), and TZV (p=0.005) differed significantly between the cancer and noncancer groups. The results of the multivariate analysis showed that PSAD (p=0.022), PSAV (p<0.001), and TPV (p=0.037) had a statistically significant correlation with cancer detection.
CONCLUSIONS
PSAD, PSAV, and TPV are predictive factors of prostate cancer in patients with an initial diagnosis of ASAP of the prostate. Although repeat biopsy is mandatory irrespective of PSA values, the follow-up of PSA may help to estimate the probability of cancer in these men.

Keyword

Diagnosis; Needle biopsy; Prostatic neoplasms

MeSH Terms

Biopsy
Biopsy, Needle
Follow-Up Studies
Humans
Male
Multivariate Analysis
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Prostate-Specific Antigen

Reference

1. Mearini L, Costantini E, Bellezza G, Cavaliere A, Zucchi A, Bini V, et al. Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int. 2008. 81:29–35.

2. Hyun CL, Lee HE, Kim H, Lee HS, Park SY, Chung JH, et al. Pathological analysis of 1,000 cases of transrectal ultrasound guided systematic prostate biopsy: establishment of new sample processing method and diagnostic utility of immunohistochemistry. Korean J Pathol. 2006. 40:406–419.

3. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med. 2000. 124:98–107.

4. Oh JW, Kim YB, Yang SO, Lee JK, Kim YJ, Jung TY, et al. Prostate cancer detection rate of rebiopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate. Korean J Urol. 2009. 50:237–240.

5. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, et al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. Urology. 1998. 51:749–757.

6. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006. 175:820–834.

7. Scattoni V, Roscigno M, Freschi M, Briganti A, Fantini GV, Bertini R, et al. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology. 2005. 66:1043–1047.

8. Borboroglu PG, Sur RL, Roberts JL, Amling CL. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol. 2001. 166:866–870.

9. Park S, Shinohara K, Grossfeld GD, Carroll PR. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol. 2001. 165:1409–1414.

10. Epstein JI. How should atypical prostate needle biopsies be reported? Controversies regarding the term 'ASAP'. Hum Pathol. 1999. 30:1401–1402.

11. Samaratunga H, Gardiner RA, Yaxley J, Brown I. Atypical prostatic glandular proliferations on needle biopsy: diagnostic implications, use of immunohistochemistry, and clinical significance. Anal Quant Cytol Histol. 2006. 28:104–110.

12. Iczkowski KA. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med. 2006. 130:835–843.

13. Iczkowski KA, Chen HM, Yang XJ, Beach RA. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology. 2002. 60:851–854.

14. Fadare O, Wang S, Mariappan MR. Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med. 2004. 128:557–560.

15. Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology. 1999. 53:351–355.

16. Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F. Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy"). Eur Urol. 2006. 50:666–674.

17. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002. 62:2220–2226.

18. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002. 287:1662–1670.

19. Zhou M, Aydin H, Kanane H, Epstein JI. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol. 2004. 28:239–243.

20. Adley BP, Yang XJ. Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol. 2006. 28:1–13.

21. Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu PG, Tretiakova MS, et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004. 45:218–225.

22. Ficarra V, Novella G, Novara G, Galfano A, Pea M, Martignoni G, et al. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol. 2005. 48:932–937.

23. Brausi M, Castagnetti G, Dotti A, De Luca G, Olmi R, Cesinaro AM. Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment? J Urol. 2004. 172:906–908.

24. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2005. 3:Suppl 1. S29–S33.

25. Allen EA, Kahane H, Epstein JI. Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology. 1998. 52:803–807.